ATE411276T1 - Kristalle eines hydroxynorephedrinderivats - Google Patents

Kristalle eines hydroxynorephedrinderivats

Info

Publication number
ATE411276T1
ATE411276T1 AT02765352T AT02765352T ATE411276T1 AT E411276 T1 ATE411276 T1 AT E411276T1 AT 02765352 T AT02765352 T AT 02765352T AT 02765352 T AT02765352 T AT 02765352T AT E411276 T1 ATE411276 T1 AT E411276T1
Authority
AT
Austria
Prior art keywords
hydroxynorephedine
crystals
derivative
methylethylüaminoüethylü
dimethylphenoxyüacetate
Prior art date
Application number
AT02765352T
Other languages
English (en)
Inventor
Hidetoshi Isawa
Yukihiko Hotei
Kiyoshi Kasai
Junichi Sonehara
Satoshi Akahane
Hiromu Harada
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of ATE411276T1 publication Critical patent/ATE411276T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02765352T 2001-09-13 2002-08-27 Kristalle eines hydroxynorephedrinderivats ATE411276T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001277345 2001-09-13

Publications (1)

Publication Number Publication Date
ATE411276T1 true ATE411276T1 (de) 2008-10-15

Family

ID=19101883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02765352T ATE411276T1 (de) 2001-09-13 2002-08-27 Kristalle eines hydroxynorephedrinderivats

Country Status (28)

Country Link
US (1) US7208520B2 (de)
EP (1) EP1426355B1 (de)
JP (1) JP4157036B2 (de)
KR (2) KR100874952B1 (de)
CN (1) CN1275936C (de)
AT (1) ATE411276T1 (de)
AU (1) AU2002330453B2 (de)
BR (1) BR0212494A (de)
CA (1) CA2458544C (de)
CO (1) CO5560555A2 (de)
CY (1) CY1109409T1 (de)
DE (1) DE60229404D1 (de)
DK (1) DK1426355T3 (de)
EA (1) EA006022B1 (de)
EC (1) ECSP045017A (de)
ES (1) ES2314092T3 (de)
HR (1) HRP20040250A2 (de)
HU (1) HUP0401694A3 (de)
IL (2) IL160681A0 (de)
MX (1) MXPA04002449A (de)
NO (1) NO328252B1 (de)
NZ (1) NZ531602A (de)
PL (1) PL206246B1 (de)
PT (1) PT1426355E (de)
SI (1) SI1426355T1 (de)
UA (1) UA77000C2 (de)
WO (1) WO2003024916A1 (de)
ZA (1) ZA200401757B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ES2309513T3 (es) * 2003-05-05 2008-12-16 Kissei Pharmaceutical Co., Ltd. Uso de derivados de acido fenoxiacetico para tratar vejiga hiperactiva.
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
CA2580170A1 (en) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
EP1809591A1 (de) 2004-10-26 2007-07-25 Kissei Pharmaceutical Co., Ltd. Synthese von phenoxyessigsäurederivaten
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US8003694B2 (en) 2005-04-26 2011-08-23 Kissei Pharmaceutical Co., Ltd. Crystal of hydroxynorephedrin derivative hydrochloride ¼ hydrate
EP1878719A4 (de) * 2005-04-26 2010-10-06 Kissei Pharmaceutical Kristallpolymorph eines hydroxynorephedrin­deriva­thydro­chlorids
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
KR20140143461A (ko) 2007-08-06 2014-12-16 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
SI2712622T1 (sl) 2008-05-21 2016-10-28 Ferring B.V. Orodisperzibilni dezmopresin za povečanje začetnega obdobja spanja nemotenega z nokturijo
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP4005731B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体の結晶多形
JP4005729B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005730B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形

Also Published As

Publication number Publication date
EP1426355A4 (de) 2006-03-29
KR20080098691A (ko) 2008-11-11
HUP0401694A2 (hu) 2004-11-29
MXPA04002449A (es) 2004-07-23
ECSP045017A (es) 2004-09-27
HUP0401694A3 (en) 2008-03-28
CA2458544C (en) 2010-08-17
KR20040044881A (ko) 2004-05-31
CN1553890A (zh) 2004-12-08
SI1426355T1 (sl) 2009-02-28
IL160681A0 (en) 2004-08-31
DK1426355T3 (da) 2009-02-23
HRP20040250A2 (en) 2005-02-28
US20040242686A1 (en) 2004-12-02
PL367874A1 (en) 2005-03-07
CY1109409T1 (el) 2014-07-02
ZA200401757B (en) 2005-03-03
EA200400311A1 (ru) 2004-08-26
EP1426355A1 (de) 2004-06-09
JP4157036B2 (ja) 2008-09-24
US7208520B2 (en) 2007-04-24
PL206246B1 (pl) 2010-07-30
CN1275936C (zh) 2006-09-20
CA2458544A1 (en) 2003-03-27
AU2002330453B2 (en) 2008-04-17
EA006022B1 (ru) 2005-08-25
HK1070051A1 (en) 2005-06-10
WO2003024916A1 (en) 2003-03-27
DE60229404D1 (de) 2008-11-27
ES2314092T3 (es) 2009-03-16
NO20041060L (no) 2004-06-11
PT1426355E (pt) 2008-11-03
EP1426355B1 (de) 2008-10-15
NO328252B1 (no) 2010-01-18
CO5560555A2 (es) 2005-09-30
BR0212494A (pt) 2004-08-24
KR100874952B1 (ko) 2008-12-19
UA77000C2 (en) 2006-10-16
JPWO2003024916A1 (ja) 2004-12-24
IL160681A (en) 2010-06-16
NZ531602A (en) 2006-01-27

Similar Documents

Publication Publication Date Title
DE60229404D1 (de) Kristalle eines hydroxynorephedrinderivats
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
SE0104334D0 (sv) Therapeutic agents
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
SE0201544D0 (sv) Novel compounds and thier use
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
CA2315235A1 (en) Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
WO2000056315A8 (en) Treatment of pain
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
ATE295845T1 (de) Prucaloprid-n-oxid
MXPA01009461A (es) Tratamiento de osteoartritis.
WO2005035500A3 (en) Therapeutic agents useful for treating pain
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto
SE0302666D0 (sv) Novel Compounds
DE60117472D1 (de) Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit
ITTO20040343A1 (it) Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1426355

Country of ref document: EP